Exagen Reports 2025 Revenue of $67M, Achieving 20% Growth
- Revenue Growth: Exagen anticipates total revenue for 2025 to be between $66 million and $67 million, reflecting a year-over-year growth of 19% to 20%, indicating strong performance and sustained demand in its market.
- Increased Testing Volume: The volume of AVISE CTD tests is projected to reach between 136,000 and 137,000, representing an increase of at least 13,000 tests compared to 2024, showcasing the company's success in product promotion and market acceptance.
- Average Selling Price Increase: The trailing 12-month average selling price for AVISE CTD is expected to rise by $30, reaching between $441 and $445, demonstrating effective strategies in enhancing product value and profitability.
- Strong Cash Position: By the end of 2025, Exagen's cash and cash equivalents are projected to be $32 million, a $10 million increase from 2024, which strengthens the company's financial flexibility for future investments and innovations.
Trade with 70% Backtested Accuracy
Analyst Views on XGN
About XGN
About the author
Exagen Reports 2025 Revenue of $67M, Achieving 20% Growth
- Revenue Growth: Exagen's total revenue for 2025 reached $67 million, marking a 20% year-over-year increase, which demonstrates the company's strong performance and sustained customer demand in its market.
- Test Volume Increase: The AVISE CTD test volume reached between 136,000 and 137,000, an 11% increase over 2024, indicating significant progress in expanding market share and customer base.
- Cash Position: Year-end cash and cash equivalents stood at $32 million, a $10 million increase from 2024, enhancing the company's ability to invest in innovation and expand operations in the future.
- Price Increase: The trailing 12-month average selling price for AVISE CTD rose to $445, up $30 from 2024, reflecting the company's success in enhancing product value and market positioning.
Exagen Reports 2025 Revenue of $67M, Achieving 20% Growth
- Revenue Growth: Exagen anticipates total revenue for 2025 to be between $66 million and $67 million, reflecting a year-over-year growth of 19% to 20%, indicating strong performance and sustained demand in its market.
- Increased Testing Volume: The volume of AVISE CTD tests is projected to reach between 136,000 and 137,000, representing an increase of at least 13,000 tests compared to 2024, showcasing the company's success in product promotion and market acceptance.
- Average Selling Price Increase: The trailing 12-month average selling price for AVISE CTD is expected to rise by $30, reaching between $441 and $445, demonstrating effective strategies in enhancing product value and profitability.
- Strong Cash Position: By the end of 2025, Exagen's cash and cash equivalents are projected to be $32 million, a $10 million increase from 2024, which strengthens the company's financial flexibility for future investments and innovations.
New Factors Influencing Exagen's Story
Exagen's Fair Value and Growth Outlook: Exagen's long-term fair value remains at approximately $15.43 per share, with revenue growth expectations steady at around 15.14%, driven by the expanding adoption of AVISE CTD in autoimmune diagnostics.
Analyst Ratings and Price Targets: B. Riley initiated a Buy rating with a $15 price target, while Canaccord raised its target from $11 to $15, both highlighting the potential of AVISE CTD as a leading diagnostic tool despite sector challenges.
Sector Challenges and Company Confidence: Canaccord warns of pressures in the life science tools sector due to tariffs and funding uncertainties, but Exagen maintains its revenue guidance of $65M to $70M for 2025, aiming for positive adjusted EBITDA by Q4 2025.
Dynamic Investor Narratives: Investors are encouraged to follow Exagen's evolving narrative on Simply Wall St, which connects company performance with future forecasts, helping to inform buy or sell decisions based on the latest updates and market conditions.
BTIG Reaffirms Buy Rating on Exagen, Increases Price Target to $15
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies to improve trading outcomes.
Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.
Booking Holdings Expected to Surge by 12%? Check Out 10 Leading Analyst Predictions for Monday
Analyst Rating Changes: Several Wall Street analysts have adjusted their price targets and ratings for various companies, including DraftKings, Avidity Biosciences, and Glaukos Corp, reflecting a mix of upgrades and downgrades.
Notable Price Target Increases: Avidity Biosciences saw its price target raised significantly by Bernstein, while Exagen and Estee Lauder also received upward adjustments from Canaccord Genuity.
Upgrades and Downgrades: Glaukos Corp was upgraded by Wells Fargo, while Kura Sushi USA experienced a downgrade from Benchmark, despite both maintaining Buy ratings.
Current Stock Prices: The article provides the latest closing prices for the mentioned stocks, indicating market performance and analyst sentiment.
Changing Perspectives on Exagen Amid Analyst Upgrades and Growth Indicators
Analyst Price Target Increase: Exagen's consensus analyst price target has risen from $11.17 to $13.14, indicating a more optimistic valuation due to improved business performance and the potential of its AVISE CTD diagnostic platform.
Bullish Analyst Sentiment: Analysts from B. Riley, Cantor Fitzgerald, and KeyBanc have expressed positive outlooks, with B. Riley initiating coverage with a Buy rating and a $15 target, while Cantor Fitzgerald and KeyBanc also raised their price targets, highlighting strong operational results and revenue guidance.
S&P Global BMI Index Inclusion: Exagen has been added to the S&P Global BMI Index, which may enhance its visibility and credibility in the investment community, alongside projecting a revenue range of $65 million to $70 million for fiscal year 2025.
Future Financial Expectations: The company anticipates achieving positive adjusted EBITDA by Q4 2025 if it meets its revenue targets, with slight adjustments in discount rates and net profit margin outlooks reflecting a higher projected earnings valuation.
Exagen Reports 2025 Revenue of $67M, Achieving 20% Growth
- Revenue Growth: Exagen's total revenue for 2025 reached $67 million, marking a 20% year-over-year increase, which demonstrates the company's strong performance and sustained customer demand in its market.
- Test Volume Increase: The AVISE CTD test volume reached between 136,000 and 137,000, an 11% increase over 2024, indicating significant progress in expanding market share and customer base.
- Cash Position: Year-end cash and cash equivalents stood at $32 million, a $10 million increase from 2024, enhancing the company's ability to invest in innovation and expand operations in the future.
- Price Increase: The trailing 12-month average selling price for AVISE CTD rose to $445, up $30 from 2024, reflecting the company's success in enhancing product value and market positioning.
Exagen Reports 2025 Revenue of $67M, Achieving 20% Growth
- Revenue Growth: Exagen anticipates total revenue for 2025 to be between $66 million and $67 million, reflecting a year-over-year growth of 19% to 20%, indicating strong performance and sustained demand in its market.
- Increased Testing Volume: The volume of AVISE CTD tests is projected to reach between 136,000 and 137,000, representing an increase of at least 13,000 tests compared to 2024, showcasing the company's success in product promotion and market acceptance.
- Average Selling Price Increase: The trailing 12-month average selling price for AVISE CTD is expected to rise by $30, reaching between $441 and $445, demonstrating effective strategies in enhancing product value and profitability.
- Strong Cash Position: By the end of 2025, Exagen's cash and cash equivalents are projected to be $32 million, a $10 million increase from 2024, which strengthens the company's financial flexibility for future investments and innovations.
New Factors Influencing Exagen's Story
Exagen's Fair Value and Growth Outlook: Exagen's long-term fair value remains at approximately $15.43 per share, with revenue growth expectations steady at around 15.14%, driven by the expanding adoption of AVISE CTD in autoimmune diagnostics.
Analyst Ratings and Price Targets: B. Riley initiated a Buy rating with a $15 price target, while Canaccord raised its target from $11 to $15, both highlighting the potential of AVISE CTD as a leading diagnostic tool despite sector challenges.
Sector Challenges and Company Confidence: Canaccord warns of pressures in the life science tools sector due to tariffs and funding uncertainties, but Exagen maintains its revenue guidance of $65M to $70M for 2025, aiming for positive adjusted EBITDA by Q4 2025.
Dynamic Investor Narratives: Investors are encouraged to follow Exagen's evolving narrative on Simply Wall St, which connects company performance with future forecasts, helping to inform buy or sell decisions based on the latest updates and market conditions.
BTIG Reaffirms Buy Rating on Exagen, Increases Price Target to $15
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies to improve trading outcomes.
Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.
Booking Holdings Expected to Surge by 12%? Check Out 10 Leading Analyst Predictions for Monday
Analyst Rating Changes: Several Wall Street analysts have adjusted their price targets and ratings for various companies, including DraftKings, Avidity Biosciences, and Glaukos Corp, reflecting a mix of upgrades and downgrades.
Notable Price Target Increases: Avidity Biosciences saw its price target raised significantly by Bernstein, while Exagen and Estee Lauder also received upward adjustments from Canaccord Genuity.
Upgrades and Downgrades: Glaukos Corp was upgraded by Wells Fargo, while Kura Sushi USA experienced a downgrade from Benchmark, despite both maintaining Buy ratings.
Current Stock Prices: The article provides the latest closing prices for the mentioned stocks, indicating market performance and analyst sentiment.
Changing Perspectives on Exagen Amid Analyst Upgrades and Growth Indicators
Analyst Price Target Increase: Exagen's consensus analyst price target has risen from $11.17 to $13.14, indicating a more optimistic valuation due to improved business performance and the potential of its AVISE CTD diagnostic platform.
Bullish Analyst Sentiment: Analysts from B. Riley, Cantor Fitzgerald, and KeyBanc have expressed positive outlooks, with B. Riley initiating coverage with a Buy rating and a $15 target, while Cantor Fitzgerald and KeyBanc also raised their price targets, highlighting strong operational results and revenue guidance.
S&P Global BMI Index Inclusion: Exagen has been added to the S&P Global BMI Index, which may enhance its visibility and credibility in the investment community, alongside projecting a revenue range of $65 million to $70 million for fiscal year 2025.
Future Financial Expectations: The company anticipates achieving positive adjusted EBITDA by Q4 2025 if it meets its revenue targets, with slight adjustments in discount rates and net profit margin outlooks reflecting a higher projected earnings valuation.
